Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 550

Results For "GE"

8420 News Found

Briefs: J. B. Chemicals & Pharmaceuticals, Dr. Reddy’s Laboratories and Piramal Enterprises
News | December 26, 2022

Briefs: J. B. Chemicals & Pharmaceuticals, Dr. Reddy’s Laboratories and Piramal Enterprises

J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.


Advent International to acquire a significant stake in Suven Pharmaceuticals
News | December 26, 2022

Advent International to acquire a significant stake in Suven Pharmaceuticals

Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.


Searchlight Pharma to acquire Miravo Healthcare
News | December 26, 2022

Searchlight Pharma to acquire Miravo Healthcare

Miravo to remain a Canadian controlled and operated company following closing of the transaction


Granules India appoints Mukesh Surana as CFO
People | December 24, 2022

Granules India appoints Mukesh Surana as CFO

Surana is a chartered accountant with an all-India rank.


Lupin receives USFDA approval for Brivaracetam Tablets
Drug Approval | December 23, 2022

Lupin receives USFDA approval for Brivaracetam Tablets


Zydus receives final approval and 180 days shared exclusivity from USFDA for Selexipag Tablets
Drug Approval | December 23, 2022

Zydus receives final approval and 180 days shared exclusivity from USFDA for Selexipag Tablets

Selexipag tablet is indicated in adults for the treatment of pulmonary arterial hypertension to delay disease progression and reduce the risk of hospitalization for PAH


Strides Pharma Global receives AUD 94 mn for sale of Australia's operations
News | December 23, 2022

Strides Pharma Global receives AUD 94 mn for sale of Australia's operations

The balance of AUD 94 Million was a deferred consideration backed by a secured interest-bearing instrument


Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer
Clinical Trials | December 22, 2022

Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer

First PARP inhibitor and new hormonal agent combination approved for these patients in Europe


Supriya Lifescience signs solar agreement with Enrich Energy
Sustainability | December 22, 2022

Supriya Lifescience signs solar agreement with Enrich Energy

The project will generate and supply green energy to fulfill about 50% present consumption of the company